Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

BUY
$0.76 - $1.82 $12,758 - $30,554
16,788 New
16,788 $16.8 Million
Q4 2022

Feb 14, 2023

BUY
$0.64 - $0.91 $10,744 - $15,277
16,788 New
16,788 $11,000
Q2 2022

Aug 15, 2022

SELL
$0.75 - $1.33 $96,516 - $171,155
-128,688 Reduced 88.46%
16,788 $15,000
Q1 2022

May 11, 2022

SELL
$1.29 - $4.04 $4,392 - $13,756
-3,405 Reduced 2.29%
145,476 $192,000
Q4 2021

Feb 11, 2022

BUY
$3.45 - $6.05 $11,816 - $20,721
3,425 Added 2.35%
148,881 $573,000
Q3 2021

Nov 12, 2021

BUY
$5.53 - $9.28 $156,471 - $262,577
28,295 Added 24.15%
145,456 $813,000
Q2 2021

Aug 11, 2021

SELL
$7.84 - $12.6 $5.79 Million - $9.3 Million
-738,187 Reduced 86.3%
117,161 $1.04 Million
Q1 2021

May 13, 2021

BUY
$10.54 - $19.3 $862,066 - $1.58 Million
81,790 Added 10.57%
855,348 $10.9 Million
Q4 2020

Feb 09, 2021

BUY
$12.79 - $17.1 $220,742 - $295,128
17,259 Added 2.28%
773,558 $10.8 Million
Q3 2020

Nov 12, 2020

BUY
$12.99 - $19.41 $243,042 - $363,161
18,710 Added 2.54%
756,299 $9.85 Million
Q2 2020

Aug 12, 2020

BUY
$12.19 - $22.96 $7.71 Million - $14.5 Million
632,522 Added 602.02%
737,589 $12.9 Million
Q1 2020

May 06, 2020

BUY
$10.08 - $27.21 $97,151 - $262,249
9,638 Added 10.1%
105,067 $1.63 Million
Q4 2019

Feb 14, 2020

BUY
$13.05 - $21.88 $98,879 - $165,784
7,577 Added 8.62%
95,429 $1.92 Million
Q3 2019

Nov 07, 2019

BUY
$14.12 - $23.44 $533,919 - $886,336
37,813 Added 75.57%
87,852 $1.24 Million
Q2 2019

Aug 12, 2019

BUY
$13.21 - $27.29 $63,672 - $131,537
4,820 Added 10.66%
50,039 $814,000
Q1 2019

May 14, 2019

BUY
$12.46 - $22.05 $240,253 - $425,168
19,282 Added 74.34%
45,219 $997,000
Q4 2018

Feb 11, 2019

BUY
$15.43 - $32.7 $150,936 - $319,871
9,782 Added 60.55%
25,937 $431,000
Q3 2018

Nov 09, 2018

BUY
$26.95 - $52.7 $435,377 - $851,368
16,155 New
16,155 $0

Others Institutions Holding AVRO

# of Institutions
1
Shares Held
559K
Call Options Held
0
Put Options Held
0

About AVROBIO, Inc.


  • Ticker AVRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,773,900
  • Description
  • AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...
More about AVRO
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.